Drug industry should watch proposed parallel reviews by FDA, CMS

02/19/2008 | RPM Report (free registration), The

FDA and CMS officials say a parallel review process could speed marketing approval and reimbursement, but industry experts say the program could delay products from reaching the market and add to cost and data requirements. Biotech and pharma companies may not feel an immediate impact because the program is voluntary, affects mostly device firms and is years from implementation, but the industry still should monitor signs of closer cooperation between the agencies, according to this RPM Report analysis.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX